Business
Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 20
About this update from Nkarta, Inc.
[{"type":"image","alt":"Nkarta, Inc.","displaySize":"","headline":null,"caption":"Nkarta, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E3HnIhM4alJb8N_ScZ3_Cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0","width":300,"height":78}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment","length":181,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":181,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Ntrust-1 expanded to include primary membranous nephropathy cohort","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":66,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients","length":162,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":162,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":90,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029","length":137,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":137,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.","length":277,"tagName":"p"},{"type":"text","content":"“Our recent restructuring and continued efforts at cost containment have positioned us well to achieve our clinical ...